Literature DB >> 6297913

Intermittent ketoconazole therapy of chronic mucocutaneous candidiasis in childhood.

S Fanconi, R Seger, P Joller, C Issler, G Schär.   

Abstract

We report the clinical and laboratory findings in two children with chronic mucocutaneous candidiasis (CMC) treated successfully with intermittent long-term ketoconazole therapy. Both had chronic infection of the nails, skin and mucous membranes with positive cultures for candida. Both were resistant to multiple local and systemic antifungal agents. After institution of ketoconazole therapy there was a dramatic improvement with clearing of the oral (one week), skin (two months) and nail lesions (5 months). After 8 months the drug was stopped and clinical remission persisted for 10 and 7 months respectively. Relapse of oral candidiasis was treated with a short course of ketoconazole (4-16 weeks) leading to complete healing of the lesions. Clinical improvement was not related to an amelioration in lymphocyte transformation. There was no change in the progressive deterioration of the lymphocyte responses to candida antigen which was probably due to persisting candida cell wall components (e.g. mannan).

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6297913     DOI: 10.1007/bf01377351

Source DB:  PubMed          Journal:  Eur J Pediatr        ISSN: 0340-6199            Impact factor:   3.183


  26 in total

1.  Miconazole in the treatment of chronic mucocutaneous candidiasis: a preliminary report.

Authors:  T J Fischer; R B Klein; H E Kershnar; T C Borut; E R Stiehm
Journal:  J Pediatr       Date:  1977-11       Impact factor: 4.406

2.  Treatment of chronic oral candidiasis with clotrimazole troches. A controlled clinical trial.

Authors:  C H Kirkpatrick; D W Alling
Journal:  N Engl J Med       Date:  1978-11-30       Impact factor: 91.245

3.  Defective cellular immunity associated with chronic mucocutaneous moniliasis and recurrent staphylococcal botryomycosis: immunological reconstitution by allogeneic bone marrow.

Authors:  R H Buckley; Z J Lucas; B G Hattler; C M Zmijewski; D B Amos
Journal:  Clin Exp Immunol       Date:  1968-02       Impact factor: 4.330

4.  Prolonged oral treatment of chronic mucocutaneous candidiasis with Amphotericin B.

Authors:  L F Montes; M D Cooper; L G Bradford; R O Lauderdale; C D Taylor
Journal:  Arch Dermatol       Date:  1971-07

Review 5.  Strategies in the treatment of systemic fungal infections.

Authors:  G Medoff; G S Kobayashi
Journal:  N Engl J Med       Date:  1980-01-17       Impact factor: 91.245

6.  A multi-center, double-blind comparison of ketoconazole and griseofulvin in the treatment of infections due to dermatophytes.

Authors:  R Legendre; M Steltz
Journal:  Rev Infect Dis       Date:  1980 Jul-Aug

7.  Successful treatment of chronic mucocutaneous candidiasis with ketoconazole.

Authors:  H M Rosenblatt; W Byrne; M E Ament; J Graybill; E R Stiehm
Journal:  J Pediatr       Date:  1980-10       Impact factor: 4.406

8.  Treatment of chronic mucocutaneous candidiasis with ketoconazole: a controlled clinical trial.

Authors:  E A Petersen; D W Alling; C H Kirkpatrick
Journal:  Ann Intern Med       Date:  1980-12       Impact factor: 25.391

9.  Turbidimetric studies of growth inhibition of yeasts with three drugs: inquiry into inoculum-dependent susceptibility testing, time of onset of drug effect, and implications for current and newer methods.

Authors:  J N Galgiant; D A Stevens
Journal:  Antimicrob Agents Chemother       Date:  1978-02       Impact factor: 5.191

10.  Chronic mucocutaneous candidiasis with a serum-dependent neutrophil defect: response to ketoconazole.

Authors:  C T Kennedy; H Valdimarsson; R J Hay
Journal:  J R Soc Med       Date:  1981-02       Impact factor: 18.000

View more
  1 in total

1.  Immunological observations before and after successful treatment of chronic mucocutaneous candidiasis with ketoconazole and transfer factor.

Authors:  L Corbeel; J L Ceuppens; G Van den Berghe; H Claeys; M Casteels-Van Daele
Journal:  Eur J Pediatr       Date:  1984-11       Impact factor: 3.183

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.